Compare ONEW & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | ZURA |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.7M | 455.4M |
| IPO Year | 2019 | 2021 |
| Metric | ONEW | ZURA |
|---|---|---|
| Price | $9.62 | $4.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $16.50 | $13.00 |
| AVG Volume (30 Days) | 76.3K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $3.69 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $1.88 |
| 52 Week High | $17.35 | $7.25 |
| Indicator | ONEW | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 30.51 | 35.03 |
| Support Level | $8.99 | $4.36 |
| Resistance Level | $9.83 | $5.87 |
| Average True Range (ATR) | 0.70 | 0.36 |
| MACD | -0.24 | -0.13 |
| Stochastic Oscillator | 5.85 | 6.58 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.